Entries by LRuas

Novo Nordisk Foundation grants DKK 25 million ($3.3 million) for completion of clinical trial to improve treatment outcomes for people with critical limb ischaemia

/in

The grant will enable leading international researchers to complete a clinical trial comparing the two most common treatment methods for preventing leg amputation among people with critical limb ischaemia. Critical limb ischaemia is a serious and debilitating disease that affects about 22 million people globally, and these are often people with diabetes and/or chronic kidney […]

AMSilk Invited to Participate in VISION 2045 Summit

/in

Leaders from across the world will convene at VISION 2045 Summit which takes place alongside COP27 (the U.N. Climate Change Conference) in November AMSilk will be attending and participating in a panel discussion at the Vision 2045 Summit on ‘Commerce and Industry: What’s Next?’ Munich, Germany, 2 November 2022 – AMSilk GmbH (“AMSilk”), a world leader […]

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

/in

Funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities Plans to expand platform beyond hemophilia A 02 November 2022, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million in a Series A financing […]

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022

/in ,

Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]

© Optimum Strategic Communications.